Market Overview

Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade

Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade
Related LLY
40 Stocks Moving In Friday's Pre-Market Session
The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

The case for buying shares of Eli Lilly and Co (NYSE: LLY) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes franchise, according to Goldman Sachs. 

The Analyst

Goldman Sachs' Jami Rubin downgraded Eli Lilly rating from Buy to Neutral with a price target lowered from $98 to $95.

The Thesis

Despite the downgrade, Eli Lilly still offers investors an attractive long-term story with a diversified portfolio that could offer margin expansion over time, Rubin said in a Tuesday note. (See the analyst's track record here.) 

But here are some risks to the company's diabetes franchise, particularly Trulicity, which happens to be the company's "biggest and fastest" growth driver, she said. 

Trulicity's risk profile has grown recently due to the following factors, Rubin said: 

  • Greater share gains from Novo Nordisk A/S (ADR) (NYSE: NVO)'s competing therapy Victoza after its CV label in June 2017. 
  • Heightened competition from injectable semaglutide. 
  • Potential negative impact from Novo Nordisk's oral semaglutide product, especially if data that's expected to arrive in 2018 is successful. 

The three headline risks are reason enough for investors to move to the sidelines, especially ahead of baricitinib's data release this year and ongoing questions surrounding the drug's safety, according to Goldman Sachs. 

Price Action

Shares of Eli Lilly were trading lower by 1.51 percent at the time of publication. 

Related Links:

7 Catalysts For Eli Lilly Over The Next Year

Argus Shares Eli Lilly's Optimism, Upgrades To Buy

Latest Ratings for LLY

Nov 2018CitigroupDowngradesBuyNeutral
Oct 2018Credit SuisseUpgradesUnderperformNeutral
Oct 2018Wolfe ResearchInitiates Coverage OnPeer Perform

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: baricitinib Diabetes Goldman Sachs Jami RubinAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (LLY + NVO)

View Comments and Join the Discussion!

Latest Ratings

PANWBMO CapitalUpgrades240.0
UAAGoldman SachsUpgrades28.0
GPSGoldman SachsDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Mid-Day Market Update: Blackhawk Surges On News Of Acquisition By Silver Lake; Eiger Biopharmaceuticals Shares Slide

8 Stocks Getting Hit By Bitcoin's Regulatory Woes